Last reviewed · How we verify
tenofovir, lamivudine, efavirenz
This is a fixed-dose combination of three antiretroviral drugs that inhibit HIV reverse transcriptase and integrase to suppress viral replication.
This is a fixed-dose combination of three antiretroviral drugs that inhibit HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection (treatment and prevention).
At a glance
| Generic name | tenofovir, lamivudine, efavirenz |
|---|---|
| Also known as | at 4 weeks versus at 12 weeks after tuberculosis treatment |
| Sponsor | Bamrasnaradura Infectious Diseases Institute |
| Drug class | Antiretroviral combination therapy (NRTI/NtRTI/NNRTI) |
| Target | HIV reverse transcriptase, HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Tenofovir is a nucleotide reverse transcriptase inhibitor (NtRTI), lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), and efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Together, they target different mechanisms of HIV reverse transcriptase and prevent the virus from replicating and integrating into host cell DNA. This combination is a standard first-line antiretroviral therapy regimen for HIV-1 infection.
Approved indications
- HIV-1 infection (treatment and prevention)
Common side effects
- Dizziness and CNS effects (efavirenz)
- Nausea
- Rash
- Renal impairment (tenofovir)
- Bone density loss (tenofovir)
- Headache
- Fatigue
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection (PHASE1)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028) (PHASE2)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: